Medical laboratory tests and services provider Laboratory Corp. of America Holdings (LH - Free Report) recently announced the timely completion of purchase of all the operating assets of full-service independent women's health laboratory Pathology, Inc., following the satisfaction of all closing conditions. Notably, financial terms of this deal have been kept under wraps.
The acquisition, which is aimed at expanding the company’s women’s health testing business, includes Pathology, Inc.’s patient service centers used to conduct its medical testing and services business.
Pathology, Inc.’s forte is in reproductive FDA donor testing and anatomic, molecular and digital pathology services. The impending acquisition includes Pathology, Inc.’s patient service centers, which are used to conduct its medical testing and services business.
According to LabCorp, the company’s purchase of Pathology, Inc. is a strategic fit as the latter perfectly complements LabCorp’s existing women’s health service offerings and supports its mission to provide world class diagnostic solutions. Impressively, the transaction meets LabCorp’s financial criteria of being accretive to earnings in the first year and to earn cost of capital by the third year.
Of late, LabCorp has strengthened its foothold in the diagnostics space through both organic and inorganic means. Strategic acquisitions and collaborations with leading companies and academic institutions should help the company provide a wider portfolio of tests. The company continues to increase its scale and competencies in clinical laboratory medicine through acquisitions ranging from routine capabilities to highly esoteric testing.
Apart from its mega $6.1 billion acquisition of Covance, completed in Feb 2015; in recent times, LabCorp has acquired LipoScience – a premier esoteric laboratory focused on personalized diagnostics for cardiovascular and metabolic disorders and Bode Technology Group, Inc. – a provider of specialized forensic DNA analysis, proprietary DNA collection products and relationship testing. Both the acquisitions are consistent with the company’s efforts to consolidate its presence in the personalized diagnostics testing market for cardiovascular and metabolic disorders as well in the forensics and DNA identification testing space.
With awareness on the rise globally, women’s health testing is currently emerging as a rapidly evolving area of medicine. We believe, meaningful acquisitions like that of Pathology, Inc. will allow LabCorp’s customers advanced access to high-quality testing, going ahead.
Currently, LabCorp has a Zacks Rank #3 (Hold). Some of the better-ranked med/dental-supply stocks are The Cooper Companies Inc. (COO - Free Report) , Henry Schein, Inc. (HSIC - Free Report) and Cardiovascular Systems Inc. (CSII - Free Report) . All the three stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>